KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Gains from Sales and Divestitures: 2015-2017

  • BeOne Medicines' Gains from Sales and Divestitures rose 504.68% to $268,750 in Q4 2017 from the same period last year, while for Dec 2017 it was $268,750, marking a year-over-year increase of 504.68%. This contributed to the annual value of $268,750 for FY2017, which is 504.68% up from last year.
  • As of Q4 2017, BeOne Medicines' Gains from Sales and Divestitures stood at $268,750, which was up 504.68% from $44,445 recorded in Q4 2016.
  • In the past 5 years, BeOne Medicines' Gains from Sales and Divestitures registered a high of $533,333 during Q4 2015, and its lowest value of $44,445 during Q4 2016.
  • In the last 3 years, BeOne Medicines' Gains from Sales and Divestitures had a median value of $268,750 in 2017 and averaged $282,176.
  • Per our database at Business Quant, BeOne Medicines' Gains from Sales and Divestitures tumbled by 91.67% in 2016 and then spiked by 504.68% in 2017.
  • BeOne Medicines' Gains from Sales and Divestitures (Quarterly) stood at $533,333 in 2015, then slumped by 91.67% to $44,445 in 2016, then skyrocketed by 504.68% to $268,750 in 2017.
  • Its Gains from Sales and Divestitures stands at $268,750 for Q4 2017, versus $44,445 for Q4 2016 and $533,333 for Q4 2015.